Skip to main content

Table 2 Characteristics of studies and the schedule of drug administration among the included studies

From: Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial

Study Cases Sex(M/F) Age (year) Type of patients Stage Grade Comparison Dosage of intervention Follow-up
Dong 2017 [16] 28 NA NA NMIBC NA NA GEM 1000 mg weekly for 8 weeks followed by monthly instillations 12 months
MMC 20 mg weekly for 8 weeks followed by monthly instillations
Lin 2016 [17] 84 56/28 GEM:61 ± 4.2
MMC:62 ± 3.5
NMIBC Tis: 3
Ta: 24
T1: 59
G1: 40 G2: 27
G3: 17
GEM 1000 mg weekly for 8 weeks followed by monthly instillations (a total of 1 year or 2 years) 24 months
MMC 30 mg weekly for 8 weeks followed by monthly instillations (a total of 1 year or 2 years)
Sun 2016 [18] 58 45/13 GEM: 37 ~ 83
MMC: 31 ~ 81
NMIBC NA NA GEM 1000 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year) 2 years
MMC 20 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)
Xiaohong 2015 [19] 56 45/11 GEM:51.26 ± 13.42
MMC:51.64 ± 12.39
NMIBC Tis: 1
Ta: 10
T1: 45
G1: 13 G2: 41
G3: 2
GEM 1000 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year) 1 year
MMC 40 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)
Raffaele 2010 [20] 109 93/16 GEM: 64.9 ± 10.5
MMC: 67.9 ± 10.2
NMIBC Ta: 72
T1: 37
G1: 25
G2: 55
G3: 29
GEM 2000 mg weekly for 6 weeks followed by 10 monthly infusion during the first year 36 months
MMC 40 mg weekly for 4 weeks followed by 10 monthly infusion during the first year
  1. M Male, F Female, NMIBC Non-muscle invasive bladder cancer, GEM Gemcitabine, MMC Mitomycin, NA Not Available (Insufficient Information Provided)